Methods and compositions relating to anti-CHI3L1 antibody reagents to treat cancer

Patent metadata

Field	Value
Publication number	US-10766968-B2
Application number	US-201816124575-A
Country	US
Kind code	B2
Filing date	Sep 7, 2018
Priority date	Aug 23, 2017
Publication date	Sep 8, 2020
Grant date	Sep 8, 2020

Abstract

It is demonstrated herein that inhibitors of immune checkpoints and CHI3L1 are synergistic. Accordingly, described herein are methods and compositions relating to combinatorial therapies for cancer, e.g., comprising an inhibitor of CHI3L1; and an inhibitor of an immune checkpoint protein. In some embodiments, the CHI3L1 inhibitor can be an antibody or antibody reagent as described herein.

First claim

What is claimed herein is:

1. A method of treating cancer in a subject in need thereof, the method comprising administering:
a) an antibody, antibody reagent, or antigen-binding fragment thereof, that specifically binds to PD-1; and
b) an inhibitor of CHI3L1, wherein the inhibitor of CHI3L1 is an immunoglobulin antibody that comprises light chain CDRs having the amino acid sequences of SEQ ID NOs: 4-6 and heavy chain CDRs having the amino acid sequences of SEQ ID NOs: 1-3,
wherein the cancer expresses PD-L1 and CHI3L1.

2. The method of claim 1 , wherein the inhibitor of CHI3L1 binds a CHI3L1 polypeptide at an epitope selected from SEQ ID NO: 13.

3. The method of claim 1 , wherein the cancer is a primary cancer or a metastatic cancer.

4. The method of claim 1 , wherein the cancer is malignant cancer.

5. The method of claim 1 , wherein the cancer is selected from the group consisting of: prostate cancer, colon cancer, rectal cancer, ovarian cancer, kidney cancer, breast cancer, glioblastoma, melanoma, malignant melanoma, and lung cancer.

6. The method of claim 1 , wherein the antibody, antibody reagent, or antigen-binding fragment thereof, that specifically binds to PD-1 is selected from the group consisting of:
pembrolizumab; nivolumab and pidilizumab.

7. The method of claim 1 , wherein the subject is a subject determined to have a level of CHI3L1 that is increased compared to a prior assessment of the level in that subject.

8. The method of claim 7 , wherein the CHI3L1 is circulating CHI3L1.

Assignees

• Univ Brown

Inventors

• Elias Jack A
• Lee Chun Geun
• He Chuan Hua
• Ma Bing
• Kamle Suchitra
• Lee Chang-Min

Classifications

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/73

  Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K16/40 Primary

  against enzymes · CPC title